1. Home
  2. ENTA vs PROF Comparison

ENTA vs PROF Comparison

Compare ENTA & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • PROF
  • Stock Information
  • Founded
  • ENTA 1995
  • PROF N/A
  • Country
  • ENTA United States
  • PROF Canada
  • Employees
  • ENTA N/A
  • PROF N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • PROF Medical/Dental Instruments
  • Sector
  • ENTA Health Care
  • PROF Health Care
  • Exchange
  • ENTA Nasdaq
  • PROF Nasdaq
  • Market Cap
  • ENTA 164.6M
  • PROF 134.3M
  • IPO Year
  • ENTA 2013
  • PROF N/A
  • Fundamental
  • Price
  • ENTA $7.84
  • PROF $4.13
  • Analyst Decision
  • ENTA Strong Buy
  • PROF Strong Buy
  • Analyst Count
  • ENTA 5
  • PROF 1
  • Target Price
  • ENTA $20.20
  • PROF $11.00
  • AVG Volume (30 Days)
  • ENTA 164.6K
  • PROF 56.4K
  • Earning Date
  • ENTA 08-11-2025
  • PROF 11-06-2025
  • Dividend Yield
  • ENTA N/A
  • PROF N/A
  • EPS Growth
  • ENTA N/A
  • PROF N/A
  • EPS
  • ENTA N/A
  • PROF N/A
  • Revenue
  • ENTA $64,806,000.00
  • PROF $11,840,000.00
  • Revenue This Year
  • ENTA N/A
  • PROF $60.07
  • Revenue Next Year
  • ENTA $1.65
  • PROF $121.80
  • P/E Ratio
  • ENTA N/A
  • PROF N/A
  • Revenue Growth
  • ENTA N/A
  • PROF 59.81
  • 52 Week Low
  • ENTA $4.09
  • PROF $3.76
  • 52 Week High
  • ENTA $13.37
  • PROF $9.17
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 45.61
  • PROF 39.16
  • Support Level
  • ENTA $7.28
  • PROF $3.76
  • Resistance Level
  • ENTA $8.86
  • PROF $4.21
  • Average True Range (ATR)
  • ENTA 0.53
  • PROF 0.20
  • MACD
  • ENTA -0.18
  • PROF 0.03
  • Stochastic Oscillator
  • ENTA 29.63
  • PROF 39.78

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

Share on Social Networks: